Kalshi and Polymarket launch FDA drug approval prediction markets
Kalshi launched prediction markets on clinical drug trials and FDA decisions in July 2026. The contracts let users trade on pharmaceutical outcomes including trial results and regulatory approvals. The new category expands Kalshi's offerings beyond sports and politics into biotech. Polymarket has also introduced FDA drug approval markets. The launches have drawn concerns about insider trading, since drug company employees, trial investigators, and regulators may possess material non-public information.
Biotech executives and clinical investigators now face temptation to trade on trial data they control before public disclosure. The CFTC has no settled framework for policing material non-public information in event contracts, so enforcement will lag any abuse. For Kalshi, the biotech vertical diversifies revenue away from sports contracts now threatened by congressional bans and state litigation.
The platform that builds credible surveillance first — trade-pattern monitoring, participant screening, or mandatory disclosure windows — could shape whether regulators impose blunt restrictions or tailored rules. Institutional investors already use equity options to hedge drug-pipeline risk; event contracts competing for that flow must prove cleaner than the alternatives. A single insider-trading scandal in this thin market would invite the same age-verification and integrity demands the NFL is pressing on sports contracts, but with biotech's higher scientific stakes and congressional attention.
Adds a live trading layer to the biotech pilot Kalshi debuted earlier this month with AppliedXL, turning a data-partnership announcement into an active vertical open to retail and institutional positions.